Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Claims30
A method, comprising treating a human being with dextromethorphan by administering once or twice daily for at least eight consecutive days a combination of dextromethorphan and bupropion to the human being, wherein the human being is an extensive metabolizer of dextromethorphan, wherein the combination is administered in a dosage form, which prior to being administered to the human being, has been shown to be effective for providing an AUC0-12 of dextromethorphan of about 700 ng·hr/mL to about 1050 ng·hr/mL to an average human being that is an extensive metabolizer of dextromethorphan after eight consecutive days of administering the dosage form, and wherein, prior to being administered to the human being, it has been shown that after eight consecutive days of administering the dosage form to an average human being that is an extensive metabolizer of dextromethorphan, the AUC0-12 of dextromethorphan is at least about 15 times the AUC0-12 of dextromethorphan that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days.
A method for treating a human being with dextromethorphan, comprising administering to the human being dextromethorphan and bupropion once or twice daily for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan, wherein dextromethorphan and bupropion are administered in a dosage form, which prior to being administered to the human being, has been shown to be effective for providing a Cmax of dextromethorphan of about 60 ng/mL to about 110 ng/mL to an average human being that is an extensive metabolizer of dextromethorphan after eight consecutive days of administering the dosage form, and wherein, prior to being administered to the human being, it has been shown that after eight consecutive days of administering the dosage form to an average human being that is an extensive metabolizer of dextromethorphan, the Cmax of dextromethorphan is at least about 15 times the Cmax of dextromethorphan that would result from administering the same amount of dextromethorphan without bupropion.
Dependencies are inferred from the claim text.